Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma

Summary

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Timeline

Start

2019-06-11

Primary completion

2020-03-31

Completion

2021-12-31

Publications

• Du Y, Dai J, Mao L, Wei X, Bai X, Chen L, Lin J, Chi Z, Cui C, Sheng X, Lian B, Tang B, Wang X, Yan X, Li S, Zhou L, Guo J, Chen Y, Si L. Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):93-101. doi: 10.1111/jdv.19467. Epub 2023 Sep 4.

Drugs

Indications